Navigation Links
Nigeria Launches Seven Billion Dollar Case Against Pfizer

The Nigerian government took a seven billion dollar (5.2 billion euro) negligence suit against the world's biggest pharmaceutical company Pfizer to court Tuesday, as the US giant demanded the charges be dismissed.

But the government's case suffered an early setback when the court rejected a request to allow it to submit "additional facts", before presiding judge Babs Kwewumi adjourned the trial to July 20.

Government lawyer Babatunde Irukera had asked to be allowed to introduce additional documents to the court, which would make it impossible for Pfizer to invoke the statute of limitations, as the alleged offences date from 1996.

The government is seeking damages after nearly 200 children either died or suffered deformities following trials for a new drug the US multinational carried out in the mid-1990s.

Nigeria has based its case on claims that Pfizer had no authorisation or parental consent to carry out the trial in Africa's most populous country. Pfizer insists it had full approval for the tests.

The drugs trial took place in the northern province of Kano in 1996, but the government only brought the case on June 4.

After the hearing, Irukera told journalists the additional facts were linked to what he said was an undertaking by Pfizer during separate earlier legal proceedings in the United States.

"In exchange for having those cases dismissed before the US court, Pfizer agreed it would not raise any type of defence that could ... suggest this action occurred 11 years ago and as a result it is statute barred," he said.

The government feared that Pfizer would renege on this undertaking, he said.

Lawyers told AFP that there were grounds in Nigerian law for arguing that the case filed 11 years later by the Nigerian government should have been brought within a maximum of six years from the alleged facts.

The drug trial was carri ed out in the northern city of Kano when there was an epidemic of meningitis, measles and cholera.

Nigeria filed a lawsuit June 4 against Pfizer for allegedly administering a test antibiotic called Trovan without authorisation or parental consent among children at a field hospital in the heart of the epidemic in Kano.

A similar suit was filed a couple of weeks earlier by authorities in Kano, Nigeria's largest state, which is seeking 2.75 billion dollars from Pfizer.

"In the midst of the epidemic, Pfizer devised a scheme under which it misrepresented and failed to disclose its primary motive in seeking to participate in giving care to the victims of the epidemic," the Kano state said in its suit.

Kano State has started both civil and criminal proceedings. The federal government has brought only a civil case.

Pfizer's lawyer Afe Babalola told journalists after Tuesday's hearing that the government case was unfounded.

"I found that there is no truth whatsoever in the claim by the federal government that my client did not obtain approval from the National Food and Drug Administration Council, NAFDAC, before coming to this place," he said.

"There are documents showing that before Pfizer came .. they wrote to the federal government and the federal government accepted and welcomed them," he continued.

"There was nothing fraudulent or surreptitious which my client did."

In Kano, the justice commissioner who filed the Kano State suits against Pfizer on behalf of the state and families of the victims, said he would accept an out-of-court settlement on the issue of compensation.

"If the defendants shows willingness to settle out of court ... we can do that with the consent of the victims and their families," Aliyu Umar, told AFP

He also said he favoured consolidating the two civil suits.

"But on the criminal sui t, no matter how long it takes, we will pursue it to its conclusion," Umar said.

Of the 200 children affected, 11 died while many more -- reportedly 181 -- suffered from deafness, paralysis, brain damage and blindness, according to the allegations.

The US Food and Drug Administration (FDA) cleared Trovan for adult use in 1997 and the drug swiftly became established as one of the most prescribed antibiotics in the US market.

It was later associated with reports of liver damage and deaths, prompting the FDA in 1999 to restrict its use to serious adult cases.

That same year, European drug regulators recommended its suspension from the European market, a decision that has since been made permanent, according to the Pfizer website.

The Nigerian government is also suing several of the company's current and former executives, all of whom are represented by different counsel.


'"/>




Related medicine news :

1. Nigerian girl recovering well after removal of brain tumor
2. Bird Flu Appears In Nigeria
3. Nigerian Farmers To Import Bird Flu Vaccine From Israel
4. Bird flu in Nigeria spreads its wings to southern states
5. Chicken Farmers In Northern Nigeria Face Huge Losses
6. Meningitis Kills 5 In Nigeria
7. Meningitis Outbreak in Nigeria Claims Five Lives
8. Fresh Outbreak Of Bird Flu In Nigeria
9. US Offers Specialized Equipment To Fight Bird Flu In Nigeria
10. One Nigerian Cocaine Pedellar Nabbed
11. Bird Flu Detected In Remote Nigerian State
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... 2017 , ... Ushio America proudly introduces the new ... solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts so ... lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s easy ...
(Date:4/28/2017)... Md. (PRWEB) , ... April 28, 2017 , ... ... Association of America (UCAOA) and College of Urgent Care Medicine will host industry ... workshops, sessions and speakers will help those in the industry adapt to the ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled in ... activity and sleep monitoring solutions for the global scientific community. The company’s new ...
(Date:4/28/2017)... ... 28, 2017 , ... Rob Lowe is a popular actor that has been ... to an educational purpose as the host of the “Informed” series. The program focuses ... recent episode, the series focuses on thyroid cancer. , Although thyroid cancer is an ...
(Date:4/27/2017)... ... April 27, 2017 , ... Healthcare companies are trying ... will rapidly reject an outdated healthcare executive resume. , “If you’re a healthcare executive ... executive resume and wondering if it’s as ready as you are for a new ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... WOONSOCKET, R.I. , April 20, 2017 /PRNewswire/ ... (NYSE: CVS), today unveiled a new store design ... new assortment of healthier food, health-focused products and ... the store to help customers discover new offerings. ... represent the next evolution of the customer experience ...
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
Breaking Medicine Technology: